Modulation by tyrosine phosphorylation of ionotropic and metabotropic responses of alpha7 nicotinic receptor

CHRESTIA, J.F.; BRUZZONE, A.; ESANDI, M.C.; BOUZAT, C.B.

Jornada; Primeras Jornadas Virtuales de la Sociedad Argentina de Biofísica SAB 2020/Biofísica en Tiempos de COVID-19; 2020

Sociedad Argentina de Biofísica (SAB)

The α7 nicotinic acetylcholine receptor is present in neuronal and non-neuronal cells. α7 acts as a ligand-gated ion channel and as a metabotropic receptor. Its activity is associated to neurological and neurodegenerative disorders, and it plays a role in neuroprotection and inflammation. Protein phosphorylation is an important regulatory mechanism involved in physiological and pathological processes. We investigated the role of tyrosine phosphorylation of α7 intracellular domain (ICD) in its dual ionotropic/metabotropic function. In HEK cells expressing α7, single-channel activity appears as brief isolated openings and episodes of few openings in quick succession (bursts). Inhibition of Src family kinases by PP2 as well as co-expression of α7 with an inactive Src kinase increase the duration and frequency of bursts, while inhibition of tyrosine phosphatases with pervanadate decreases open and burst durations without affecting channel amplitude. A mutant α7 lacking phosphorylation sites shows longer burst durations and insensitivity to PP2, thus revealing that the two tyrosine residues in the intracellular domain (ICD) are involved in receptor modulation. Cells exposed to a specific α7 agonist (PNU-282987) show an increase of ERK1/2 phosphorylation, which is detected neither in the presence of Src family kinases inhibitors nor in cells expressing the mutant receptor lacking tyrosines. Thus, phosphorylation negatively modulates ionotropic α7 activity probably by enhancing desensitization whereas the phosphorylated state of α7-ICD is required for the metabotropic receptor responses. Since the ICD is the less conserved domain among pentameric ligand-gated ion channels, potentiation of α7 through its ICD may be an attractive strategy for specific therapies in disorders involving α7.